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Abstract
Purpose: Lung cancer is the leading cause of cancer death worldwide, but techniques for effective early diagnosis are still
lacking. Proteomics technology has been applied extensively to the study of the proteins involved in carcinogenesis. In this
paper, a classification method was developed based on principal components of surface-enhanced laser desorption/
ionization (SELDI) spectral data. This method was applied to SELDI spectral data from 71 lung adenocarcinoma patients and
24 healthy individuals. Unlike other peak-selection-based methods, this method takes each spectrum as a unity. The aim of
this paper was to demonstrate that this unity-based classification method is more robust and powerful as a method of
diagnosis than peak-selection-based methods.
Results: The results showed that this classification method, which is based on principal components, has outstanding
performance with respect to distinguishing lung adenocarcinoma patients from normal individuals. Through leaving-one-
out, 19-fold, 5-fold and 2-fold cross-validation studies, we found that this classification method based on principal
components completely outperforms peak-selection-based methods, such as decision tree, classification and regression
tree, support vector machine, and linear discriminant analysis.
Conclusions and Clinical Relevance: The classification method based on principal components of SELDI spectral data is a
robust and powerful means of diagnosing lung adenocarcinoma. We assert that the high efficiency of this classification
method renders it feasible for large-scale clinical use.
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Introduction
Lung cancer is the leading cause of cancer death worldwide,
and it ranked second among new cancer cases in the United
States in 2009 [1]. In China, the incidence of lung cancer, 35
cases per 100,000 people per year, makes it the most common
form of cancer in the country. Over 20% of cancer deaths in
China are caused by lung cancer [2]. For this reason, the
Ministry of Health of China has listed lung cancer as the most
important item on its cancer prevention and control agenda [2].
Lung cancer can be categorized into small cell lung cancer and
non-small cell lung cancer (NSCLC) according to histological
criteria. NSCLC accounts for about 85% of all cases of lung
cancer and is further categorized into the specific sub-types:
adenocarcinoma, squamous cell carcinoma, and large cell
carcinoma [3]. Due to the lack of effective techniques for early
diagnosis, most patients are at an advanced stage when dia-
gnosed, leading to the poor outcomes. The 5-year survival rate is
only about 10–15% for NSCLC [4,5].
A great deal of effort has been invested in the identification of
markers for the screening of malignancies during early diagnosis.
For example, proteomics technology has been applied extensively
to the study of proteins involved in carcinogenesis [6,7]. The latest
development in systematic analysis of protein composition in cells
(i.e., protein profiling) has shown that protein profiles are closely
aligned with cellular activities. Proteomics technology may be a
promising tool in cancer screening and diagnosis [8]. In contrast,
other high-throughput methods, such as transcriptome profiling of
mRNA and miRNA, have shown only limited power in reflecting
tumor heterogeneity [5,9,10]. In addition, protein profiling is also
highly versatile. It can be applied to different kinds of samples
including tissues and body fluids [8,10,11].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34457Surface-enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF-MS, SELDI), a high-throughput
protein profiling method, has been used successfully to distinguish
cancer from non-cancer and normal controls [9,12]. The existing
methods for analyzing SELDI spectral data include two steps, peak
screening and data analysis [13,14]. The aim of peak screening is
to identify high-quality peaks (signal-to-noise ratio .2) through
baseline subtraction, normalization, peak detection, and peak
alignment [13]. Then the data analysis was aimed to detect
significant peaks, which could be taken as biomarkers in
corresponding disease studies [15]. In case-control studies, peaks
that are significantly different between cases and controls are
detected using statistical analysis (ttest, ANOVA), or data-mining
based methods, such as the classification and regression tree model
(CART), the decision tree method (DT), the support vector
machine (SVM), and the linear discriminant approach (LDA)
[16,17]. SELDI has been applied widely in the screening of
biomarkers in prostate, pancreatic, gastric, breast, nasopharyngeal,
liver, ovarian, thyroid and lung cancers [9,10,12,18,19]. For lung
cancer screening, it has been shown to be more powerful than the
more common serum markers, such as Cyfra21-1 and NSE
[20,21]. Its utility for diagnosis and prediction of prognosis in non-
smoking patients has also been reported [22]. These peak-
selection-based methods have several limitations. First, peak-
selection-based methods focus on high peaks, which represent high
concentrations of proteins. However, the selected peaks may be
common among cases and controls and may not indicate any
difference between these two groups. Smaller peaks that differ
between groups, however, may have more predictive power.
These smaller peaks can be ignored during the peak screening
step. Second, peak-selection-based methods take peaks as
independent and ignore the information inherent in their
locations. It is believed that the combination of the peaks and
relationship among their relative locations may contain informa-
tion that is useful in group discrimination. Third, the results of
peak-selection-based methods can vary from sample to sample.
Often the tumor markers established in one study are usually
poorly validated subsequent studies, and the sensitivity and
specificity of diagnostic and prediction models are usually not
well reproduced, even within the same lab [23].
In light of these limitations, we constructed a classification
method for diagnosis or prediction of diseases based on principal
components of SELDI spectral data without peak selection. The
classification method includes two optimization steps, first screens
candidate principal components, and second hunts the optimized
model. To evaluate the performance of this classification method
based on principal components of SELDI spectral data, we
compared it to the peak-selection based methods DT, CART,
SVM, and LDA through leaving-one-out, 19-fold, 5-fold, and 2-
fold cross validation.
Materials and Methods
Patients and samples
Plasma samples from 71 lung adenocarcinoma patients were
collected from patients who underwent pulmonary resection for
primary lung cancer at Shanghai Chest Hospital. All participants
provided informed consent. The diagnosis and histological
classification of the tumors were carried out following the criteria
from AJCC (American Joint Committee on Cancer) [24]. The
demographic and clinical characteristics of the subjects are
summarized in Table 1. No patients received radiotherapy or
chemotherapy prior to surgery. Twenty-four normal samples were
collected from healthy volunteers who took physical examinations
at the same hospital. The research was conducted with the official
written approval (written form) of the Biomedical Ethics
Committee of Fudan University, Shanghai, China.
SELDI-TOF-MS
Three-microliter plasma samples were diluted with 2-fold buffer
U9 (9 M urea, 2% CHAPS, 50 mM Tris-Hcl, 1% DTT, pH 9.0)
and shaken on ice for 30 min. Then 108 mL binding buffer
(100 mM NaAc, pH 4) was added to the plasma which made a
final dilution of 39-fold. The SELDI ProteinChip arrays of weak
cation exchange (WCX-2) from Ciphergen Biosystems were used
for protein capture. Chips were put into a bioprocessor and
washed twice with 200 mL of binding buffer (50 mM NaAc, pH 4)
for each well with gentle shaking for 5 min, keeping the surface of
each spot wet. Then 100 mL of the diluted plasma was added to
each well and shaken at 4uC for 1 hour. The wells were washed
twice with 200 mL of binding buffer, followed by washing with
HPLC water. They were then allowed to dry. Then 0.5 mLo f
sinapinic acid was applied to each spot twice. The arrays were
allowed to air-dry and then subjected to SELDI analysis and, read
using a Protein-Chip reader. Seven peptides, including 1084.247-
[Arg8]-vasopressin, 1637.903-somatostatin, 2147.500-dynorphin
A, 2933.500-ACTH[1–24]human, 3495.941-insulin B-chain (bo-
vine), 5807.653-[Arg]-Insulin, and 7033.614-hirudin BKHV, were
randomly selected from an all in-one peptide standard (NP20 chip,
Ciphergen Biosystems) to calibrate the PBS-II-c ProteinChip
reader (Ciphergen Biosystems). Each spot was scanned with a laser
intensity of 185 and a detector sensitivity of 8 to acquire an
Table 1. Features of lung adenocarcinoma patients.
Pathological parameters Tumors
a Sex Age(y)
Male Female
Tumor Size
T1 5 (7.04%) 5 0 38–64
T2 46 (64.79%) 25 21 41–72
T3 10 (14.08%) 4 6 40–75
T4 10 (14.08%) 3 7 37–75
Nodal involvement
N0 25 (35.21%) 12 13 38–75
N1 25 (35.21%) 14 11 51–72
N2 21 (29.58%) 11 10 37–69
Metastasis
M0 70 (98.59%) 36 34 37–75
M1 1 (1.41%) 1 0 42
AJCC Stage
I 17 (23.94%) 11 6 38–68
II 26 (36.62%) 13 13 49–75
IIIA 18 (25.35%) 10 8 40–72
IIIB 9 (12.68%) 2 7 37–75
IV 1 (1.41%) 1 0 42
Histologic grade
Poor 28 (39.44%) 20 8 37–75
Moderate 32 (45.07%) 13 19 38–75
Good 11 (15.49%) 4 7 4172
aNumber of cases. The numbers in the parenthesis stand for the percentage.
doi:10.1371/journal.pone.0034457.t001
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evaluate the reliability and stability of our assay, data from one
plasma sample in 6 randomized chip locations was analyzed.
Data preprocessing
Suppose we have N individuals assayed by SELDI. Each
spectrum is characterized as M signal intensities at corresponding
M/Z locations. We denote the signal intensity of the m M/Z point
of individual i as Sim. In our dataset, all individuals share the same
M/Z locations, so the entire dataset can be stored in an N|M
signal intensity matrix. The following procedures are applied to
normalize multiple SELDI spectra:
(1) We extract raw signal intensity values at each M/Z location
using Ciphergen’s ProteinChipH software. No additional
processing option (background subtraction or normalization)
is employed.
(2) We perform logarithm transformation of all raw intensity
values to approximately stabilize the signal variance while
retaining the biological interpretation.
(3) For each individual, we estimate the intensity background of
each M/Z location with the median value of a sliding window.
Each sliding window is centered at the M/Z location of
interest and spans 24 M/Z points in both directions. The
median statistics are chosen for their known robustness (24)
against outliers (sharp peaks).
(4) We performed intensity background subtraction at each M/Z
point. The subtraction is performed on logarithm scale which
stands for the log-ratio of signal against background, thus the
result is still biological meaningful.
(5) We perform multiple spectrum quantile normalization.
Quantile normalization is used to minimize the bias across
different spectra, in which the intensity distribution of every
spectrum is forced to equal that of the others.
Classification method based on principal components of
SELDI spectral data
The procedures of the classification method based on principal
components of SELDI spectral data are as follows:
Step 1: Based on preprocessed data, principal com-
ponent analysis (PCA) is applied to the SELDI spectral
data to obtain orthogonal linear combinations of the
SELDI spectra.
Step 2: Candidate principal components are selected
based on group difference.
Step 3: The selected principal components are jointly
incorporated into logistic regression model and, based
on certain criteria, the optimal classification model
based on principal components of SELDI spectral data is
obtained.
In Step 2, principal components which are significantly
different between cases and controls (significance level a~0:05)
are selected in the classification method based on principal
components of SELDI spectral data. This is different from general
principles of screening principal components, eigenvalues greater
than 1 or contribution larger than 80 percent). In Step 3, the
selected principal components are jointly incorporated in logistic
regression model based on three criteria for relative logistic
regression models, R square, the Hosmer-Lemeshow statistic
(which indicates the goodness-of-fit of the classification model),
and accuracy from leaving-one-out cross validation. Then the
optimal classification model based on principal components of
SELDI spectral data is found. The accuracy of leaving-one-out
cross validation is considered more important than R square or the
Hosmer-Lemeshow statistic when the two criteria are within a
certain range.
Comparison to peak-selection-based methods
We then compared the performance of the classification method
based on principal components of SELDI spectral data here
developed to the peak-selection-based methods DT, CART, SVM
and LDA. We used leaving-one-out, 19-fold, 5-fold, and 2-fold
cross validation. The construction and cross-validation of the
classification model based on principal components of SELDI
spectral data is demonstrated above.
The peak screening processes of SELDI spectral data and data
analysis for peak-selection-based methods DT, CART, SVM, and
LDA are demonstrated below:
Step 1: Peak screening process. After baseline subtraction
and normalization, peak detection was used to eliminate any peaks
whose intensities were below a specified signal-to-noise (S/N)
threshold guided, for example, by the magnitude of the signal-to-
noise ratio (SNR, in this paper, SNR=2). Then peak alignment
was applied by generating an interval around each peak centered
at the m/z value for the peak (0.3%). Then the maximum value
was taken as the height of peak [13].
Step 2: Data analysis and cross-validation. After
screening, the data from the selected peaks was entered into the
Tanagra software package, and analysis and cross-validation of
DT, CART, SVM and LDA was performed.
Results
Reproducibility
We evaluated the reliability and stability of the technique by
analyzing data from one plasma sample in 6 randomized locations
on chips. The coefficient variations of M/Z values and protein
intensity of randomly selected proteins were ,1% (P=4.88E-04)
and 0.12 (P,0.2), respectively, confirming that SELDI-TOF-MS
offers a stable and reliable measurement.
Application of the classification method based on
principal components of SELDI spectral data
We applied the classification method based on principal
components developed in this paper to SELDI spectral data from
71 lung adenocarcinoma patients and 24 healthy controls. First,
the first seven principal components were considered in the
candidate alignment. Of these, the seventh principal component
was at the edge of the contribution curve cut-off [25,26]. Then the
logistic regression model was applied to each principal component
to assess its association with group status. The results showed that
the first principal component (PC1), sixth principal component
(PC6), and seventh principal component (PC7) were significantly
different in different groups, with P,0.01, P=0.03 and P=0.03,
respectively (Table 2). PC1 was the most significant one,
accounting for 53.9% of the difference between two groups, while
PC6 and PC7 accounted for 5% and 6%, respectively. Then PC1,
PC6, and PC7 were jointly incorporated in logistic regression
models to construct a classification model (Table 3) in which PC1
was included in all the models. All the potential classification
models had conceivable indices of goodness-of-fit (Hosmer-
Lemeshow statistic) [27]. Cross-validation results showed that
the logistic classification model based on PC1 and PC7 performed
as well as that on PC1, PC6, and PC7, with the same values of
accuracy (Table 3). The former was preferred because it was
equally efficient but more concise. The optimal classification
Classification Model Based on Principal Components
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model based on PC1 and PC7) was found to account for 61.71%
of the difference between two groups.
The explicit formulation of the optimal classification model
based on principal components of SELDI spectral data is shown in
Table 4. The relationship between principal components and
SELDI spectral data was important for selecting key M/Z points
contributing greatly to each PC. In particular, we displayed the
mean M/Z value at each point for cases and controls (Figure 1A).
The weights of PC1 and PC7 on the M/Z points are presented in
Figure 1 (Figure 1B for PC1 and Figure 1C for PC7). In Figures 1B
and 1C, the horizontal lines represent +/23*SD of corresponding
principal component weights on all M/Z points. In Figures 1B and
1C, the weights beyond the two horizontal lines indicate that the
corresponding M/Z points contributed more than other M/Z
points to the related principal component. Interestingly, Figure 1
shows that not only maximum peaks (the two M/Z points between
5,000 and 10,000) and significant peaks (M/Z points around
5,000) contributed to classification model based on principal
components of SELDI spectral data but also that those peaks were
not very high (M/Z points near zero). Figure 2 shows the result of
the optimal classification model based on principal components of
the SELDI spectral data, in which 2 cases and 2 normal
observations were misclassified.
Comparison with peak-selection based methods
The construction and cross-validation of DT, SVM, LDA, and
CART were performed using Tanagra software. The criteria used
for DT was that confidence level 0.25 and minimum size of leaves
5. The classification result of DT on 71 lung adenocarcinoma and
24 controls was shown in Figure 3. The kernel used in SVM was a
polynome with a polynome exponent of 1. The criteria used for
CART were minimum node size to split 10 and a pruning set size
of 15%.
Cross-validation results for DT, SVM, LDA, CART, and the
classification method based on principal components of SELDI
spectral data are shown in Table 5. The classification method
based on principal components here developed completely
outperformed peak-selection-based methods DT, SVM, LDA
and CART with respect to sensitivity, specificity, and accuracy as
determined by leaving-one-out, 2-fold, 5-fold, and 19-fold cross
validation. Cross-validation also showed that the performance of
the classification model based on principal components was similar
across the leaving-one-out, 19-fold, 5-fold, and 2-fold cross
validation, which indicated that it was not sensitive to sample size.
Discussion
In this paper, we propose a classification method based on
principal components of SELDI spectral data. Principal compo-
nent analysis is mathematically defined as an orthogonal linear
transformation that transforms the data into a new coordinate
system such that the greatest variance by any projection of the data
comes to lie on the first coordinate (called the first principal
component), the second greatest variance on the second
coordinate, and so on. Principal component analysis has already
been applied in SELDI data analysis. In 2001, Nilsen et al. used
principal component analysis to select peaks to visually identify
natural clusters [28]. In 2003, Lilien et al. used principal
component analysis as a dimension-reduction method [29]. Kernel
principal component analysis combined with a logistic regression
model has been applied to the study of gene expression [30].
However, most of the current methods with PCA analysis is first
using PCA to find the first couple principal components, and then
using the first couple components in a second step classification.
The first two principal components explain the biggest variability
in the spectra. However, they can be the same in cases and
controls, and may not be the most predictive of the group status.
In our method, PCA is applied to obtain orthogonal linear
combinations of SELDI spectral data. Since the final goal is to
distinguish cases from controls, the most important information is
the principal components that are different between groups, not
the ones that explain the most variability. We are the first to
emphasize selection of the principal components that are most
predictive of the group status. This is a simple yet important idea.
Unlike peak-selection-based methods, the classification method
based on principal components of SELDI spectral data took each
SELDI spectrum as a whole entity, and then PCA was applied to
the SELDI spectral data to obtain orthogonal linear combinations
of the SELDI spectra. The candidate principal components are
selected just based on group differences. Then the selected
principal components are jointly incorporated into logistic
regression model and, based on certain criteria, the optimal
classification model based on principal components of SELDI
spectral data is obtained. The classification method based on
Table 2. Candidate principal components.
PC PC1 PC2 PC3 PC4 PC5 PC6 PC7
Proportion
(%)
a
18.1 10.5 7.69 4.90 4.41 3.43 3.16
P value
b ,0.01* 0.39 0.12 0.48 0.48 0.03* 0.03*
R square
c 0.54 0.01 0.03 0.01 0.01 0.05 0.06
aContribution of each PC to the whole variation.
bP value of the coefficient testing of logistic regression analysis on each PC.
cFitness index of each logistic regression model on single PC.
doi:10.1371/journal.pone.0034457.t002
Table 3. Summary of classification models based on principal
components of SELDI spectral data.
Model R square
Hosmer-Lemeshow
statistic
Cross validation
accuracy
pc1 0.5338 3.01 (0.93) 92.63%
pc1 pc6 0.5591 1.32 (1.00) 92.63%
pc1 pc7 0.6171 0.99 (1.00) 95.79%
pc1 pc6 pc7 0.6330 0.33 (1.00) 95.79%
doi:10.1371/journal.pone.0034457.t003
Table 4. Optimal classification model based on principal
components of SELDI spectral data.
Parameter Coef (STDErr) OR (95%CL) P value
Intercept 25.49(1.92) ,0.01
PC1 4.05(1.40) 57.22(3.72, 881.07) ,0.01
PC7 25.30(2.27) 0.005(,0.001, 0.43) 0.02
Coef, coefficient.
STDErr, standard error.
OR, odds ratio.
CL, confidence level.
doi:10.1371/journal.pone.0034457.t004
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advantages. First, candidate principal components are selected
based on group differences, so principal components that account
for less variability among the data but possess more power for
group discrimination can be selected. This would ordinarily
include the PC2, which in our data was not included in the
classification model because it was not significantly different across
cases and controls. PC7 was included in the classification model
because it showed significant differences between groups while
accounting for only moderate variance among the SELDI spectra
data. We only considered the first seven principal components in
this paper, though other principal components, which were
smaller than PC7, could also be detected based on group
differences if higher power had been desired. In contrast, these
smaller principal components may be ignored in other principal-
component-based methods. Second, the classification model based
on principal components of SELDI spectral data takes into
account the pattern of the spectra, such as the combination and
the relative locations of the M/Z values, while the peak-selection-
based methods take peaks as independent entities. The principal
components are linear combinations of the whole spectra which
directly represents the differences in patterns of spectra from cases
to controls. In Figures 1B and 1C, the weights beyond the two
horizontal lines indicate that the corresponding M/Z points
contribute more than other M/Z points to the related principal
component. Interestingly, Figure 1 shows that not only maximum
peaks (the two M/Z points between 5,000 and 10,000) and peaks
that are significantly different between groups (M/Z points around
5,000) contributed to the classification model based on principal
components of SELDI spectral data but also that smaller peaks
Figure 1. M/Z means of cases and controls and the weights of PC1 and PC7 on the spectrum. A) The M/Z means of cases (red) and normal
controls (green) at each M/Z point. B) The weights of PC1 at each M/Z point. C) Weights of PC7 at each M/Z point. Horizontal lines in Figure 1B and
1C represent 3*SD of corresponding PC on the spectrum. The data used here are the normalized SELDI data obtained from 71 lung adenocarcinoma
patients and 24 normal individuals.
doi:10.1371/journal.pone.0034457.g001
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used to distinguish cases from controls along with spectra. Lastly
and most important, the reproducibility of results from the
classification method based on principal components of SELDI
spectral data was found to be better than that of peak-selection-
based methods. As shown in Table 5, the results of leaving-one-
out, 19-fold, 5-fold, and 2-fold cross-validation showed that the
sensitivity, specificity, and accuracy of our method completely
outclassed those of peak-selection-based methods (DT, CART,
SVM, and LDA).
Protein profiling using two-dimensional electrophoresis,
MALDI, SELDI, and other methods has been used for diagnosis,
classification, prognosis, and drug discovery in the study and
clinical treatment of numerous cancers [7,8,9,10,12,31,32,33].
The samples used in protein profiling have included tissues,
exhaled breath condensate, blood, and others available specimens.
Blood samples, which are minimally invasive and readily available,
are the specimens of choice for cancer screening and early
diagnosis. Successful implementation of screening in several
cancers has led to reduced mortality and improved outcomes
[10]. Although most lung cancer patients are at advanced stages
when their condition is diagnosed, the 5-year survival rate can
increase to 52% if they are diagnosed in stage I and resected at
once [34]. This is why it is a top priority to screen lung cancer and
diagnose it as early as possible. Based on these reports, in the
present study, plasma samples from lung adenocarcinoma patients
and normal controls were analyzed using the well-established
protein profiling method SELDI-TOF-MS to explore the
possibility and accuracy of lung cancer screening and early
diagnosis. The classification method based on principal compo-
nents of SELDI spectral data could be applied to other types of
spectral data, such as that collected from other types of cancer or
other tissue or fluid samples when available.
There are several reported disadvantages of SELDI-TOF-MS
[15,35]. Tumor markers that seem very accurate in one study may
have middling results in others. The same is true of marker
sensitivity and specificity, even within the same lab [23]. Many
possible reasons for this phenomenon have been suggested. The
most important possible cause of this disadvantage is the fact that
conventional peak-calling methods cannot promise full power in
discriminating cases from controls. Although a typical SELDI-
Figure 2. Classification method based on principal components
of SELDI spectral data and experimental data. Two cases and two
normal individuals had been misclassified into opposite groups. The
black squares indicate case individuals, and white squares with ‘‘V’’
shapes in the middle represent normal individuals. The data used here
are the normalized SELDI data obtained from 71 lung adenocarcinoma
patients and 24 normal individuals.
doi:10.1371/journal.pone.0034457.g002
Figure 3. Decision-tree-based classification model and exper-
imental data. Two peaks that identified using a decision-tree-based
classification model are shown, with 2 cases misclassified into control
groups. The data used here are the peaks selected through baseline
subtraction, normalization, peak detection, and peak alignment of
SELDI data obtained from 71 lung adenocarcinoma patients and 24
normal individuals.
doi:10.1371/journal.pone.0034457.g003
Table 5. Cross-validation results of DT, SVM, LDA, CART, and
our method.
Cross-validation DT SVM LDA CART Our method
Leaving-one-out
a
91.55% 95.77% 88.73% 90.14% 97.18%
87.50% 83.33% 91.67% 70.83% 91.67%
90.53% 92.63% 89.47% 85.26% 95.79%
19-fold
91.55% 94.37% 90.14% 92.96% 97.18%
87.50% 83.33% 87.50% 79.17% 91.67%
90.53% 91.58% 89.47% 89.47% 95.79%
5-fold
94.37% 94.37% 85.92% 90.14% 97.18%
79.17% 79.17% 87.50% 58.33% 91.67%
90.53% 90.53% 86.32% 82.11% 95.79%
2-flod
94.37% 94.37% 77.46% 94.37% 95.77%
62.50% 58.33% 75.00% 54.17% 91.67%
86.32% 85.26% 76.84% 84.21% 94.74%
DT, decision-tree-based classification model; SVM, support vector machine;
LDA, linear discriminant approach; CART, classification and regression tree.
aThe first line is the true positive rate (sensitivity); the second line is the true
negative rate (specificity); and the third line is accuracy.
doi:10.1371/journal.pone.0034457.t005
Classification Model Based on Principal Components
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between 500 and 20,000 M/Z values, many studies call for fewer
than 100 peaks in a SELDI spectrum analyses using software
[8,20,21,23]. This is less than what can be scored manually. We
observed that some peaks with moderate M/Z values and some
plateaus with high M/Z values were not identified by the software.
Sometimes moderate peaks and plateaus bare differentially
expressed between cases and controls. This makes them valuable
as biomarkers, indicating the disease. For example, when using the
conventional calling method with Biomarker Wizard software,
only 21 of the M/Z peaks were detected as different across the
case group and the control group. Another disadvantage of
SELDI-TOF-MS is that the proteins cannot be identified directly.
However, as mentioned above, that does not affect the accuracy of
diagnosis of lung adenocarcinoma. With the help of appropriate
methods of statistical analysis, cancer can be identified correctly by
SELDI-TOF-MS profiling. From there, diagnosis based on
proteomic signatures can be expected as a complement to routine
measurement, such as X-rays, CTs, and MRI.
Generally speaking, the classification method based on principal
components of SELDI spectral data developed in this paper is a
robust and powerful method for diagnosis of lung adenocarcino-
ma. It may become a valuable part of the toolbox of cluster and
discriminatory analysis. We propose that the high efficiency of the
classification model based on principal components of SELDI
spectral data renders it feasible for the large-scale clinical diagnosis
of lung adenocarcinoma.
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